Abstract
Angioimmunoblastic T cell lymphoma (AITL) is a distinct subtype of peripheral T cell lymphoma characterized by generalized lymphadenopathy and frequent autoimmune-like manifestations1,2. Although frequent mutations in TET2, IDH2 and DNMT3A, which are common to various hematologic malignancies3,4, have been identified in AITL5,6,7,8, the molecular pathogenesis specific to this lymphoma subtype is unknown. Here we report somatic RHOA mutations encoding a p.Gly17Val alteration in 68% of AITL samples. Remarkably, all cases with the mutation encoding p.Gly17Val also had TET2 mutations. The RHOA mutation encoding p.Gly17Val was specifically identified in tumor cells, whereas TET2 mutations were found in both tumor cells and non-tumor hematopoietic cells. RHOA encodes a small GTPase that regulates diverse biological processes. We demonstrated that the Gly17Val RHOA mutant did not bind GTP and also inhibited wild-type RHOA function. Our findings suggest that impaired RHOA function in cooperation with preceding loss of TET2 function contributes to AITL-specific pathogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Swerdlow, S.H. et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues 4th edn, 306–311 (IARC Press, Lyon, France, 2008).
de Leval, L. et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109, 4952–4963 (2007).
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).
Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009).
Lemonnier, F. et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120, 1466–1469 (2012).
Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011).
Couronné, L., Bastard, C. & Bernard, O.A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95–96 (2012).
Cairns, R.A. et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119, 1901–1903 (2012).
Rodríguez-Pinilla, S.M. et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am. J. Surg. Pathol. 32, 1787–1799 (2008).
Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69 (2011).
Chapman, M.A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467–472 (2011).
Morin, R.D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).
Bustelo, X.R., Sauzeau, V. & Berenjeno, I.M. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 29, 356–370 (2007).
Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. Nature 420, 629–635 (2002).
Ihara, K. et al. Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue. J. Biol. Chem. 273, 9656–9666 (1998).
Shimizu, T. et al. An open conformation of switch I revealed by the crystal structure of a Mg2+-free form of RHOA complexed with GDP. Implications for the GDP/GTP exchange mechanism. J. Biol. Chem. 275, 18311–18317 (2000).
Reid, T. et al. Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J. Biol. Chem. 271, 13556–13560 (1996).
Arthur, W.T., Ellerbroek, S.M., Der, C.J., Burridge, K. & Wennerberg, K. XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. J. Biol. Chem. 277, 42964–42972 (2002).
Cheng, Z. et al. Luciferase reporter assay system for deciphering GPCR pathways. Curr. Chem. Genomics 4, 84–91 (2010).
Ridley, A.J. & Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389–399 (1992).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
Mootha, V.K. et al. PGC-1α–responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
Hill, C.S., Wynne, J. & Treisman, R. The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 81, 1159–1170 (1995).
Mylona, A. et al. The essential function for serum response factor in T-cell development reflects its specific coupling to extracellular signal–regulated kinase signaling. Mol. Cell. Biol. 31, 267–276 (2011).
Fleige, A. et al. Serum response factor contributes selectively to lymphocyte development. J. Biol. Chem. 282, 24320–24328 (2007).
Karlsson, R., Pedersen, E.D., Wang, Z. & Brakebusch, C. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta 1796, 91–98 (2009).
Hébert, M. et al. Rho-ROCK–dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J. Immunol. 181, 5963–5973 (2008).
Cleverley, S.C., Costello, P.S., Henning, S.W. & Cantrell, D.A. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene 19, 13–20 (2000).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Kent, W.J. BLAT—the BLAST-like alignment tool. Genome Res. 12, 656–664 (2002).
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
Yamaguchi, T. et al. Development of an all-in-one inducible lentiviral vector for gene specific analysis of reprogramming. PLoS ONE 7, e41007 (2012).
Ory, D.S., Neugeboren, B.A. & Mulligan, R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93, 11400–11406 (1996).
Guilluy, C., Dubash, A.D. & Garcia-Mata, R. Analysis of RhoA and Rho GEF activity in whole cells and the cell nucleus. Nat. Protoc. 6, 2050–2060 (2011).
Acknowledgements
We thank Y. Okoshi, N. Obara, Y. Yokoyama, H. Nishikii, N. Kurita and M. Seki for contributing to sample collection and banking. We also thank Y. Sakashita and T. Takahashi for technical assistance, and S. Narumiya and I. Kitabayashi for efficient discussion. This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (22134006 to S.O.; 22130002, 24390241, 25112703 and 25670444 to S.C.; 25461407 to M.S.-Y.) and was supported by the Sagawa Foundation for Promotion of Cancer Research, the Naito Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research (M.S.-Y.).
Author information
Authors and Affiliations
Contributions
M.S.-Y. prepared DNA samples, sorted the tumor cells, resequenced the samples, and sorted and integrated information. T.E. analyzed the function of wild-type and mutant RHOA. K.Y. resequenced the samples and contributed to the resequencing data analyses. Y. Shiraishi, E.N., K.C., H.T. and S.M. performed bioinformatics analyses of the resequencing data. R.I. and O.N. created the model structure for mutant RHOA. Y.M., H.M., Y.K., R.N.-M., N.B.T., K.S., T.N., Y.H. and M.N. contributed to sample collection and preparation. N.T., S. Sakata, N.N. and K.T. immunostained specimens and performed pathohistological analyses. Y. Okuno and M.S. contributed to the resequencing. A.S.-O. and Yusuke Sato contributed to mRNA sequencing. K.I., Y. Ohta, J.F., S. Shimizu, T.K., Yuji Sato and T.I. collected samples. M.S.-Y., T.E., K.Y., S.O. and S.C. generated figures and tables, and wrote the manuscript. All authors participated in discussions and interpretation of the data and results.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–17, Supplementary Tables 1–14 and Supplementary Note (PDF 6808 kb)
Rights and permissions
About this article
Cite this article
Sakata-Yanagimoto, M., Enami, T., Yoshida, K. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46, 171–175 (2014). https://doi.org/10.1038/ng.2872
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2872
This article is cited by
-
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Signal Transduction and Targeted Therapy (2023)
-
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Signal Transduction and Targeted Therapy (2023)
-
DNMT3AR882H accelerates angioimmunoblastic T-cell lymphoma in mice
Oncogene (2023)
-
Moving towards biologically informed treatment strategies for T-cell lymphomas
International Journal of Hematology (2023)
-
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders
Current Hematologic Malignancy Reports (2023)